Vudalimab clinical trials
Also written XmAb20717.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses vudalimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 4
Xencor, Inc. (4) · M.D. Anderson Cancer Center (2) · Abramson Cancer Center at Penn Medicine (1) · Northwestern University (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses vudalimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare CancersSuspendedPhase 2M.D. Anderson Cancer CenterNCT05337735Written as XmAb20717
- XmAb20717 in Advanced Biliary Tract CancersCompletedPhase 2Abramson Cancer Center at Penn MedicineNCT05297903Written as XmAb20717
- Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid CancerSuspendedPhase 2Northwestern UniversityNCT05453799Written as Vudalimab
- XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate CancerCompletedPhase 2Xencor, Inc.NCT05005728Written as vudalimab + carboplatin + cabazitaxel
- Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLCTerminatedPhase 1/2Xencor, Inc.NCT06173505Written as Vudalimab + Carboplatin + Pemetrexed
- A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesActive, not recruitingPhase 2Xencor, Inc.NCT05032040Written as vudalimab
- Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)WithdrawnPhase 2M.D. Anderson Cancer CenterNCT05900648Written as XmAb20717
- A Study of XmAb®20717 in Subjects With Selected Advanced Solid TumorsCompletedPhase 1Xencor, Inc.NCT03517488Written as XmAb20717
Given beside what is tested · 1 — vudalimab is usual care or a partner of the new treatment
Codes
What other systems call vudalimab · ClinicalTrials.gg INT014873
- UNII (FDA) 4I9I5X3Z6NVUDALIMABOne source FDA
- NCI Thesaurus C150463VudalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 4I9I5X3Z6N | VUDALIMAB | One source FDA |
| NCI Thesaurus | C150463 | Vudalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.